Shanghai Exuma Biotechnology Ltd.
1 clinical trials · Sponsor
◉ Watch Shanghai Exuma Biotechnology Ltd.
| Record | Firm | Date |
|---|---|---|
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma (NCT06830031) | Shanghai Exuma Biotechnology Ltd. | 2025-03-19 |
Track Shanghai Exuma Biotechnology Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.